Naohiko Inase

5.5k citations

164 papers · 3.6k indexed · 1 hit paper · h-index 31

Pulmonary and Respiratory Medicine top 0.5%
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 73
- Inhalation and Respiratory Drug Delivery 19
- Lung Cancer Treatments and Mutations 13
- Medical Imaging and Pathology Studies 12
- Occupational and environmental lung diseases 11
Physiology top 5%
- Sarcoidosis and Beryllium Toxicity Research 16
Public Health, Environmental and Occupational Health top 2%
- Occupational exposure and asthma 28
Oncology top 5%
Microbiology top 5%
Rheumatology
- Eosinophilic Disorders and Syndromes 10

Co-authors: Yasunari Miyazaki Yasuyuki Yoshizawa Yoshio Ohtani Takumi Akashi Shuji Miyake Tomoya Tateishi Yuki Sumi Tamiko Takemura
Cited by: Pulmonary and Respiratory Medicine Physiology Public Health, Environmental and Occupational Health
Partner nations: Japan United States Canada

In The Last Decade

Naohiko Inase

157 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2017 Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Peers

Countries citing papers authored by Naohiko Inase

Since Specialization

Citations

This map shows the geographic impact of Naohiko Inase's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naohiko Inase with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naohiko Inase more than expected).

Fields of papers citing papers by Naohiko Inase

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naohiko Inase. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naohiko Inase. The network helps show where Naohiko Inase may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Naohiko Inase, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Naohiko Inase Line = papers co-authored together Naohiko Inase links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114) Hiroyuki Sakashita,Ken Uchibori,Yasuto Jin,Toshiharu Tsutsui,Takayuki Honda,Rie Sakakibara,Takahiro Mitsumura,Yoshihisa Nukui,Tsuyoshi Shirai,Masahiro Masuo,Kozo Suhara,Haruhiko Furusawa,Takaaki Yamashita,Takehiko Ohba,Kazuhito Saito,Jun Takagiwa,Yoshihiro Miyashita,Naohiko Inase,Yasunari Miyazaki	2022	3
2	Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial Takashi Ogura,Takafumi Suda,Naohiko Inase,Yasuhiko Nishioka,Arata Azuma,Masaki Okamoto,Ayako Takizawa,Tomohiro Ito,Klaus Röhr,Yoshikazu Inoue	2022	4
3	Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan Shu Hisata,Masashi Bando,Sakae Homma,Kensuke Kataoka,Takashi Ogura,Shinyu Izumi,Susumu Sakamoto,Kizuku Watanabe,Yoshinobu Saito,Yasuo Shimizu,Motoyasu Kato,Yasuhiko Nishioka,Hiromichi Hara,Yuko Waseda,Yoshinori Tanino,Kazuhiro Yatera,Seishu Hashimoto,Hiroshi Mukae,Naohiko Inase	2021	17
4	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial Yoshikazu Inoue,Takafumi Suda,Hideya Kitamura,Masaki Okamoto,Arata Azuma,Naohiko Inase,Masataka Kuwana,Shigeki Makino,Yasuhiko Nishioka,Takashi Ogura,Ayako Takizawa,Hiroyuki Ugai,Susanne Stowasser,Rozsa Schlenker‐Herceg,Tsutomu Takeuchi	2021	10
5	Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment Ken Uchibori,Naohiko Inase,Makoto Nishio,Naoya Fujita,Ryohei Katayama	2018	23
6	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancerbreakdown → Ken Uchibori,Naohiko Inase,Mitsugu Araki,Mayumi Kamada,Shigeo Sato,Yasushi Okuno,Naoya Fujita,Ryohei Katayama	2017	329
7	Chronic Hypersensitivity Pneumonitis With a Usual Interstitial Pneumonia-Like Pattern Sahoko Chiba,Kimitake Tsuchiya,Takumi Akashi,Masahiro Ishizuka,Tsukasa Okamoto,Haruhiko Furusawa,Tomoya Tateishi,Mitsuhiro Kishino,Yasunari Miyazaki,Ukihide Tateishi,Tamiko Takemura,Naohiko Inase	2016	57
8	Validation of Inhalation Provocation Test in Chronic Bird-Related Hypersensitivity Pneumonitis and New Prediction Score Masahiro Ishizuka,Yasunari Miyazaki,Tomoya Tateishi,Toshiharu Tsutsui,Kimitake Tsuchiya,Naohiko Inase	2015	32
9	The Amount of Avian Antigen in Household Dust Predicts the Prognosis of Chronic Bird-related Hypersensitivity Pneumonitis Toshiharu Tsutsui,Yasunari Miyazaki,Jin Kuramochi,Keisuke Uchida,Yoshinobu Eishi,Naohiko Inase	2015	34
10	The c-jun N-terminal kinase signaling pathway regulates airway smooth muscle cell proliferation Sahoko Chiba,Yuki Sumi,Kaori Okayasu,Tsukasa Okamoto,Tomoya Tateishi,Haruhiko Furusawa,Kimitake Tsuchiya,Toshihide Fujie,Meiyo Tamaoka,Hiroyuki Sakashita,Yasunari Miyazaki,Naohiko Inase	2014	2
11	Esophageal bypass for the treatment of bronchoesophageal fistula in a case of squamous cell carcinoma of the lung Ken Uchibori,Kozo Suhara,Sahoko Chiba,Kimitake Tsuchiya,Toshihide Fujie,Meiyo Tamaoka,Hiroyuki Sakashita,Naohiko Inase	2013	0
12	Three Cases of Sarcoidosis in Hypersensitivity Pneumonitis Haruhiko Furusawa,Yasunari Miyazaki,Kimitake Tsuchiya,Naohiko Inase	2013	2
13	Proteome Analysis of Bronchoalveolar Lavage Fluid in Chronic Hypersensitivity Pneumonitis Tsukasa Okamoto,Yasunari Miyazaki,Ryutaro Shirahama,Meiyo Tamaoka,Naohiko Inase	2012	26
14	Serial High-Resolution Computed Tomography Findings of Acute and Chronic Hypersensitivity Pneumonitis Induced by Avian Antigen Tomoya Tateishi,Yoshio Ohtani,Tamiko Takemura,Takumi Akashi,Yasunari Miyazaki,Naohiko Inase,Yasuyuki Yoshizawa	2011	56
15	The Pathogenesis of Chronic Hypersensitivity Pneumonitis in Common With Idiopathic Pulmonary Fibrosis Torahiko Jinta,Yasunari Miyazaki,Masato Kishi,Takumi Akashi,Tamiko Takemura,Naohiko Inase,Yasuyuki Yoshizawa	2010	36
16	Chromosome 9p deletion in squamous metaplasia in cystic lesion of the lung Megumi Sawada,Naohiko Inase,Miwa Imai,Yoshio Ohtani,Shuji Miyake,Hideki Akamatsu,Yasuyuki Yoshizawa	2003	0
17	Inhalation Provocation Tests in Chronic Bird Fancier's Lung Yoshio Ohtani,Kaoru Kojima,Yuki Sumi,Megumi Sawada,Naohiko Inase,Shuji Miyake,Yasuyuki Yoshizawa	2000	106
18	Cases of Gingival Metastasis from Lung Cancer and a Review of the Literature. Michiko Tanaka,Megumi Sawada,Naohiko Inase,Masahiko Ichioka,Yutaka Usui,Yasuyuki Yoshizawa	1999	8
19	Acute Lung Injury after Inhalation of Water-Proofing Spray while Smoking a Cigarette Yasuto Jinn,Norikazu Akizuki,Minoru Ohkouchi,Naohiko Inase,M Ichioka,Fumiaki Marumo	1998	11
20	Pulmonary clear cell carcinoma Naohiko Inase,Shigemitsu Takayama,Morito Nakayama,Hirotaro Miura,Yuji Kimula	1991	2

About Naohiko Inase

Naohiko Inase is a scholar working on Pulmonary and Respiratory Medicine, Microbiology and Physiology, having authored 164 papers that have together received 3.6k indexed citations. Recurring topics across this work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (73 papers), Occupational exposure and asthma (28 papers), Inhalation and Respiratory Drug Delivery (19 papers), Sarcoidosis and Beryllium Toxicity Research (16 papers), Lung Cancer Treatments and Mutations (13 papers), Medical Imaging and Pathology Studies (12 papers), Occupational and environmental lung diseases (11 papers) and Eosinophilic Disorders and Syndromes (10 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.5k citations), Physiology (731 citations) and Public Health, Environmental and Occupational Health (732 citations). Naohiko Inase has collaborated with scholars based in Japan, United States and Canada. Frequent co-authors include Yasunari Miyazaki, Yasuyuki Yoshizawa, Yoshio Ohtani, Takumi Akashi, Shuji Miyake, Tomoya Tateishi, Yuki Sumi, Tamiko Takemura, Ken Uchibori and Haruhiko Furusawa.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact